The clinical utility of next generation sequencing in endometrial cancer: focusing on molecular subtyping and lynch syndrome
NGS enables precise molecular typing of endometrial carcinoma through the identification of mutations in the <i>POLE</i>, <i>TP53</i>, and MMR genes. Conducting germline mutation testing for MMR genes in all patients with endometrial carcinoma can effectively prevent instances of overlooked LS diagnoses. Nevertheless, the extensive expenses associated with NGS necessitate additional validation and investigation before its clinical implementation can be fully endorsed.
Authors
- Yongzhen Guo
- Chengquan Zhao (ORCID: https://orcid.org/0000-0001-7524-3048)
- Guangwei Yan (ORCID: https://orcid.org/0000-0002-9859-7727)
- Yixuan Liu (ORCID: https://orcid.org/0000-0001-6529-3527)
- Pei Zhang (ORCID: https://orcid.org/0000-0003-0608-5677)
- Xianxu Zeng (ORCID: https://orcid.org/0000-0002-0457-9908)
Institutions
- Magee-Womens Hospital (US)
- University of Pittsburgh Medical Center (US)
- Third Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Genetics
- Published
- 2024-09-05
- DOI
- https://doi.org/10.3389/fgene.2024.1440971
- Citations
- 5
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.91